Prot #GS-US-312-0117: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date9/28/129/28/18

Funding

  • PPD Development (Prot #GS-US-312-0117)
  • Gilead Sciences, Inc. (Prot #GS-US-312-0117)